Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
77 hedge funds and large institutions have $15.8M invested in Infinity Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 26 reducing their positions, and 29 closing their positions.
272% more call options, than puts
Call options by funds: $227K | Put options by funds: $61K
17% less funds holding
Funds holding: 93 → 77 (-16)
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
50% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 26
59% less capital invested
Capital invested by funds: $38.6M → $15.8M (-$22.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.39M |
| 2 |
E
Ergoteles
New York
|
+$322K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$245K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$85.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$76.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.2M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$521K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$468K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$431K |
INFI Hedge Fund Activity: Q2 2022 in Review
77 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2022, worth a combined $15.8M — down 59% from $38.6M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of INFI and 15 opened new positions — a net loss of 14 holders — while 26 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, adding an estimated $1.39M. The largest seller was BlackRock, cutting an estimated $3.27M.
- 77 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2022, down from 93 in Q1 2022.
- Funds reported $15.8M of Infinity Pharmaceuticals, Inc. stock for Q2 2022, down 59% quarter-over-quarter.
- 15 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2022 and 29 closed out, a net change of -14 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2022 was Millennium Management, an estimated $1.39M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2022 was BlackRock, an estimated $3.27M sold.
Based on aggregated 13F filings for Q2 2022.